Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 3/20 | 0.37 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.36 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.36 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.36 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.36 |
| ▸ | GRM4 | Q14833 | 4/20 | 0.35 |
| ▸ | NTRK1 | P04629 | 3/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.34 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
| ▸ | CACNA1H | O95180 | 3/20 | 0.33 |
| ▸ | ANO1 | Q5XXA6 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16675943 | 0.83 | GRM4 (0.40) | TRPA1KCNQ3KCNQ2KCNQ1SCN5A | |
| SCHEMBL16675928 | 0.76 | NPC1 (0.39) | NTRK1PARP1CACNA1HANO1 | |
| SCHEMBL16682182 | 0.75 | CACNA1H (0.41) | PARP1CACNA1HANO1 | |
| SCHEMBL16675967 | 0.68 | GSK3B (0.36) | MAPK1ANO1 | |
| SCHEMBL19976765 | 0.67 | NTRK1 (0.41) | NTRK1ANO1 | |
| SCHEMBL19976802 | 0.67 | KDR (0.36) | KCNQ3KCNQ2MAPK1 | |
| SCHEMBL19976730 | 0.66 | HDAC6 (0.41) | MAPK1 | |
| SCHEMBL19976726 | 0.66 | ABL1 (0.41) | NTRK1 | |
| SCHEMBL19976849 | 0.65 | HDAC6 (0.36) | KCNQ3KCNQ2KCNQ1GRM4MAPK1 | |
| SCHEMBL16675968 | 0.64 | AURKA (0.32) | KCNQ3KCNQ2PARP1ANO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9580391-B2 | Saturated acyl guanidine for inhibition of F1F0-ATPase | LYCERA CORPORATION (US) | 2017-02-28 | — | — | US | disclosed |
| US-9580391-B2 | Saturated acyl guanidine for inhibition of F1F0-ATPase | LYCERA CORPORATION (US) | 2017-02-28 | — | — | US | disclosed |
| US-20150119439-A1 | SATURATED ACYL GUANIDINE FOR INHIBITION OF F1F0-ATPASE | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2015-04-30 | — | — | US | disclosed |
| US-20150119439-A1 | SATURATED ACYL GUANIDINE FOR INHIBITION OF F1F0-ATPASE | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2015-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150119439-A1 | SATURATED ACYL GUANIDINE FOR INHIBITION OF F1F0-ATPASE | ATP5F1A, ATP5F1D, ATP5F1C | TRPA1 4248/4885KCNQ3 2418/4885KCNQ2 1756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.